BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27025340)

  • 61. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
    Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
    J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Discovery of potent and orally bioavailable 17β-hydroxysteroid dehydrogenase type 3 inhibitors.
    Harada K; Kubo H; Abe J; Haneta M; Conception A; Inoue S; Okada S; Nishioka K
    Bioorg Med Chem; 2012 May; 20(10):3242-54. PubMed ID: 22512907
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
    Lawrence HR; Vicker N; Allan GM; Smith A; Mahon MF; Tutill HJ; Purohit A; Reed MJ; Potter BV
    J Med Chem; 2005 Apr; 48(8):2759-62. PubMed ID: 15828812
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Allan GM; Lawrence HR; Cornet J; Bubert C; Fischer DS; Vicker N; Smith A; Tutill HJ; Purohit A; Day JM; Mahon MF; Reed MJ; Potter BV
    J Med Chem; 2006 Feb; 49(4):1325-45. PubMed ID: 16480268
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Synthesis and preliminary evaluation of a modified estradiol-core bearing a fused γ-lactone as non-estrogenic inhibitor of 17β-hydroxysteroid dehydrogenase type 1.
    Ouellet E; Ayan D; Poirier D
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5510-3. PubMed ID: 21782424
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Characterization of type 12 17beta-hydroxysteroid dehydrogenase, an isoform of type 3 17beta-hydroxysteroid dehydrogenase responsible for estradiol formation in women.
    Luu-The V; Tremblay P; Labrie F
    Mol Endocrinol; 2006 Feb; 20(2):437-43. PubMed ID: 16166196
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Rational design of 17β-hydroxysteroid dehydrogenase type3 for improving testosterone production with an engineered Pichia pastoris.
    Ding J; You S; Zhang J; Zhang H; Wang H; Zhang W; Qi W; Su R; He Z
    Bioresour Technol; 2021 Dec; 341():125833. PubMed ID: 34455250
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Altered expression of 3β-HSD, CYP17 and 17β-HSD in the foetal porcine gonads in response to anti-androgen flutamide exposure.
    Knapczyk-Stwora K; Grzesiak M; Slomczynska M
    Reprod Domest Anim; 2014 Oct; 49(5):725-33. PubMed ID: 25130044
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Identification of oxazolidinediones and thiazolidinediones as potent 17β-hydroxysteroid dehydrogenase type 3 inhibitors.
    Harada K; Kubo H; Tanaka A; Nishioka K
    Bioorg Med Chem Lett; 2012 Jan; 22(1):504-7. PubMed ID: 22137341
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Novel N-methylsulfonamide and retro-N-methylsulfonamide derivatives as 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors with good ADME-related physicochemical parameters.
    Perspicace E; Giorgio A; Carotti A; Marchais-Oberwinkler S; Hartmann RW
    Eur J Med Chem; 2013 Nov; 69():201-15. PubMed ID: 24036043
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Structural basis of the multispecificity demonstrated by 17beta-hydroxysteroid dehydrogenase types 1 and 5.
    Lin SX; Shi R; Qiu W; Azzi A; Zhu DW; Dabbagh HA; Zhou M
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):38-46. PubMed ID: 16480815
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Towards the evaluation in an animal disease model: Fluorinated 17β-HSD1 inhibitors showing strong activity towards both the human and the rat enzyme.
    Abdelsamie AS; Bey E; Gargano EM; van Koppen CJ; Empting M; Frotscher M
    Eur J Med Chem; 2015 Oct; 103():56-68. PubMed ID: 26322835
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Targeted Endocrine Therapy: Design, Synthesis, and Proof-of-Principle of 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors in Bone Fracture Healing.
    Abdelsamie AS; Herath S; Biskupek Y; Börger C; Siebenbürger L; Salah M; Scheuer C; Marchais-Oberwinkler S; Frotscher M; Pohlemann T; Menger MD; Hartmann RW; Laschke MW; van Koppen CJ
    J Med Chem; 2019 Feb; 62(3):1362-1372. PubMed ID: 30645111
    [TBL] [Abstract][Full Text] [Related]  

  • 74. 6-Hydroxybenzothiophene ketones: potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) owing to favorable molecule geometry and conformational preorganization.
    Miralinaghi P; Schmitt C; Hartmann RW; Frotscher M; Engel M
    ChemMedChem; 2014 Oct; 9(10):2294-308. PubMed ID: 25044709
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Demethoxylation of curcumin enhances its inhibition on human and rat 17β-hydroxysteroid dehydrogenase 3: QSAR structure-activity relationship and in silico docking analysis.
    Ji Z; Sang J; Wang H; Xia M; Hao T; Chen L; Lu H; Wang S; Yao M; Li L; Ge RS
    Food Chem Toxicol; 2024 Apr; 186():114489. PubMed ID: 38360388
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor.
    Watanabe K; Kakefuda A; Yasuda M; Enjo K; Kikuchi A; Furutani T; Naritomi Y; Otsuka Y; Okada M; Ohta M
    Bioorg Med Chem; 2013 Sep; 21(17):5261-70. PubMed ID: 23845281
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of phenyl alkyl imidazole-based compounds as potent inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
    Owen CP; Shahid I; Olusanjo MS; Patel CH; Dhanani S; Ahmed S
    J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):117-27. PubMed ID: 18620055
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Focused libraries of 16-substituted estrone derivatives and modified e-ring steroids: inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Vicker N; Lawrence HR; Allan GM; Bubert C; Smith A; Tutill HJ; Purohit A; Day JM; Mahon MF; Reed MJ; Potter BV
    ChemMedChem; 2006 Apr; 1(4):464-81. PubMed ID: 16892382
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Reductive 17beta-hydroxysteroid dehydrogenases in the sulfatase pathway: critical in the cell proliferation of breast cancer.
    Aka JA; Mazumdar M; Lin SX
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):183-90. PubMed ID: 19038308
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
    Schuster D; Nashev LG; Kirchmair J; Laggner C; Wolber G; Langer T; Odermatt A
    J Med Chem; 2008 Jul; 51(14):4188-99. PubMed ID: 18533708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.